CARMUSTINE
Loss of Chromosome 17p
Fred Hutchinson Cancer CenterSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Loss of Chromosome 17p cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DEXAMETHASONE Fondazione EMN Italy Onlus | Phase 2 | BB |
Fludarabine Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | BB |
Cyclophosphamide City of Hope Medical Center | Phase 2 | B |
Evomela Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | B |
TACROLIMUS City of Hope Medical Center | Phase 2 | B |
View all 18 →
Same molecule, other indications
CARMUSTINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →